|
FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
Cardiac Innovations Australia will promote sales of HeartCheck™ devices to medical and retail markets
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram (“ECG”) acquisition and management software solutions, today announced that it has received clearance from the Australian Department of Health, Therapeutics Goods Administration (“TGA”) for the sale and marketing of their hand-held ECG monitoring devices known as the HeartCheck™ ECG PEN, the HeartCheck™ ECG Monitor and GEMS™ Home in Australia.
CardioComm Solutions previously announced that the Australian TGA granted a certificate for the sale of the Company’s GEMS™ WIN medical software technologies and that the Company had signed Cardiac Innovations Australia Pty. Ltd. (“Cardiac Innovations”) to be the Company’s representative and distributor of its products in Australia. The recent TGA clearance for CardioComm Solutions now provides an expanded sales opportunity for the HeartCheck™ ECG devices and associated SMART Monitoring ECG service solution into the Australian medical, allied health, and consumer markets.
The handheld HeartCheck™ ECG devices can be connected to a Windows based computer to upload recorded ECGs to CardioComm Solutions’ SMART Monitoring ECG reading service. This ECG management and interpretation solution will provide physician interpreted or technician triaged ECG reports to the consumer within one hour on a fee-for-service basis. CardioComm Solutions’ current infrastructure allows the SMART Monitoring ECG service to support ECG transmissions from anywhere globally. With the Australian clearance, the Company will be looking to expand ECG services to support arrhythmia management of patients through a localized SMART Monitoring installation and ECG call service..
CardioComm Solutions has been working to globally expand its two main business verticals involving the sale of its consumer-based, OTC HeartCheck™ ECG monitoring products and their newly released, physician/hospital focused GEMS™ WIN ECG management solutions. The Company has approvals for the sale of the HeartCheck™ devices in Canada, the United States of America, the European Union, China and Australia.
More information regarding the HeartCheck™ products and SMART monitoring solutions is available at the Company’s web site www.theheartcheck.com.
download pdf 
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
B.C.
FOR FURTHER
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking
statements
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
forward-looking information.
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Obligations).
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of
this release.
|
